Matthew J. Wieduwilt

Author

University of California San Diego ORCID

Also Known As

M. J. Wieduwilt, M. Wieduwilt, M.J. Wieduwilt, Matthew J Wieduwilt, Matthew J. Wieduwilt, Matthew Joseph Wieduwilt, Matthew Wieduwilt

142

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

University of California San Diego The University of Texas MD Anderson Cancer Center Washington University in St. Louis Moffitt Cancer Center Cleveland Clinic

About

Matthew J. Wieduwilt is an author at University of California San Diego specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	3.5K
2	Health Sciences	12	13	3K
3	Natural Sciences	1	1	52
4	Public Health	1	1	21
5	Biology	1	1	52

Matthew J. Wieduwilt

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaPharmacotherapyMetronomic ChemotherapyMyeloid NeoplasiaHematological Malignancy	2018	958
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud, Journal of the National Comprehensive Cancer Network Hematological MalignancyVersion 3.2017OncologyHealth SciencesMixed-phenotype Acute Leukemia	2017	651
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Journal of the National Comprehensive Cancer Network Hematological MalignancyHealth SciencesMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2019	418
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021 Daniel A. Pollyea, Dale L. Bixby, Alexander E. Perl, Journal of the National Comprehensive Cancer Network Hematological MalignancyTranslational MedicineOncologyMixed-phenotype Acute LeukemiaAcute Myeloid Leukemia	2021	314
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Blood	2020	307
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Patrick A. Brown, Bijal Shah, Anjali S. Advani, Journal of the National Comprehensive Cancer Network Hematological MalignancyNccn All PanelMedicinePhiladelphia ChromosomeMixed-phenotype Acute Leukemia	2021	230
Signaling Pathways Crucial for Craniofacial Development Revealed by Endothelin-A Receptor-Deficient Mice David E. Clouthier, S. Clay Williams, Hiromi Yanagisawa, Developmental Biology Pathways CrucialDevelopmental BiologyEpendymaBone Morphogenic ProteinCraniofacial Disorder	2000	210
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, The Lancet Haematology Hematological MalignancyOncologyCpx-351 Versus 7+3Mixed-phenotype Acute LeukemiaHematology	2021	200
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults Mark R. Litzow, Zhuoxin Sun, Ryan J. Mattison, New England Journal of Medicine	2024	171
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, Journal of Clinical Oncology Secondary AmlPrognosisPharmacotherapyLogistic AnalysisAntecedent Mds	2016	164

Page 1